Work

Niacinamide–Ceramide Conjugate: In Vitro Bioactivities and 28-Day Clinical Evidence for Multitarget Skincare

Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Niacinamide (NAM) and ceramides are well-established skincare ingredients with distinct yet complementary biological mechanisms. Nevertheless, simple physical blending of these two actives presents practical limitations for topical application. To address this, the present study evaluated SuperCera N-Nicotinamide(P) (NAM-Cer), a niacinamide–ceramide covalent conjugate conceived to integrate bioactivities derived from each parent moiety within a single molecular framework. Employing an integrated workflow combining in vitro cellular assays and a 28-day randomized clinical trial, we identified multiple cellular-level bioactivities of NAM-Cer, including elastase inhibition, upregulation of type I collagen (COL1A1) and aquaporin-3 (AQP3), suppression of melanogenesis and tyrosinase activity, and downregulation of matrix metalloproteinase-1 (MMP-1). Clinical evaluation revealed significant, concentration-dependent improvements in skin hydration, elasticity, firmness, brightness, and antiwrinkle efficacy, along with favorable cutaneous tolerability. In summary, NAM-Cer is a safe, multitarget skincare candidate that elicits diverse skin-beneficial bioactivities in vitro and drives concentration-dependent cutaneous improvements in short-term human topical use.
Source: ACS Omega
Language: English
Subfield: Dermatology
Field: Medicine
Open Access status: gold
Estimated APC paid: $1,935
OpenAlex ID: W7234616341
FWCI:
Cites: 31
Cited by:
Related to: 10